Navigation Links
Preventing Bone Metastasis In Patients With Breast Cancer

Based on findings of a recent study researchers say the drug clodronate is an effective treatment for patients with breast cancer that has spread to their bones. Researchers studied more than 1,000 patients // with breast cancer. Patients received standard therapy plus 1,600 milligrams of oral clodronate a day or a placebo for five years.

Results showed 124 patients in the study had their breast cancer spread to their bones. Fifty-one of these patients were treated with clodronate, and 73 of these received a placebo. Researchers say patients in the clodronate-treatment group had a decreased rate of skeletal-related events compared to those in the placebo group. Patients who received clodronate were less likely to need radiation, less likely to develop skeletal fractures, and less likely to need bone surgery. Those treated with oral clodronate also had a 2.5-year increase in survival compared to those on placebo. Patients treated with clodronate had an average survival of 2,107 days, while those on placebo had an average survival of only 1,229 days.

Thus researchers conclude saying that treatment with clodronate not only delays or prevents bone metastases in patients with breast cancer, but also reduces the incidence of skeletal-related events, morbidity, and mortality in those patients who develop bone metastases despite treatment at the time of occurrence.
'"/>




Page: 1

Related medicine news :

1. Preventing mental decline in the aged
2. Preventing white coat hypertension
3. Preventing Childhood Deaths
4. Preventing Vision Loss
5. Preventing Vision Loss
6. Preventing Colorectal Cancer
7. Preventing Prostate Cancer
8. Lycopene Can Help In Preventing Prostate Cancer
9. Heart Drug Also Effective In Preventing Specific Causes Of Death
10. Preventing cavities in children
11. Preventing Strokes Using Less Invasive Techniques
Post Your Comments:
(Date:7/18/2008)...f-the-art radiation technology impro...as, July 18 /PRNewswire/ -- Patients of Trinity Mo...logy-Tyler are among the first,in the nation to ha...that,provides faster and more accurate treatment f....newscom.com/cgi-bin/prnh/20061117/DAF023LOGO ),...
(Date:7/18/2008)...ing the benefits of resistance training in keeping...nwood, a postdoctoral research fellow with UQ and ...h investigated how people over the age of 65 respo...oking at was how simple resistance training can im...mance." Dr Henwood said. , "By building strengt...
(Date:7/18/2008)...ction to develop an integrated, comprehensive, nat... of losing its status as the global health care le...ion of Academic Health Centers (AAHC, www.aahcdc....h Macy, Jr. Foundation. , Out of Order, Out of T...rns that the nation is running out of time to ensu...
(Date:7/18/2008)...Call/ -- SyntheMed, Inc. (OTC,Bulletin Board: SYMD...nt,and commercialization of anti-adhesion, drug de...nced today the appointment of Ms. Corinne Mundin t...ional Market Development.,Ms. Mundin, who is based...ales management and market development experience ...
Breaking Medicine News(10 mins):Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 2Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 3Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 4Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 5Health News:The benefits of a little resistance for older adults 2Health News:New report warns current policies will not avert health workforce crisis 2Health News:SyntheMed Appoints Corinne Mundin as Director, International Market Development 2Health News:SyntheMed Appoints Corinne Mundin as Director, International Market Development 3
...s who are training for marathon running events may...ia (EAH) that can develop from low levels of sodiu...ened when the athletes drink excess amounts of flu... is increasing, but athletes, coaches, and medical...
...ving 3,189 school children from Denmark, Estonia a...ilies don’t necessarily have worse health compared...ucated parents. The results of the study were publ...the study challenge the results of the earlier rep...
...ear of marriage a wife may be able to control how ...abuse like the use of marijuana. However the rever...ollected showed that in the first year of marriage... likely to start or resume smoking marijuana if th...
...nning a pregnancy take a general multivitamin supp...t thing for them and their baby, however a recent ...development defects in unborn babies but many wome...multivitamin supplements say researchers based on ...
Other Medicine News:Health News:Athletes Warned Of Exercise-Associated Hyponatremia 2Health News:Wife May Determine Husband’s Marijuana Use 2
(Date:7/16/2008)... Raptor to Support Phase 2a Clinical Trial at UCSD...-- Raptor,Pharmaceuticals Corp. ("Raptor" or the "...ced the execution of a collaboration agreement (th...San Diego ("UCSD") to,include a Phase 2a clinical ... cysteamine bitartrate ("Cysteamine") in adolescen...
(Date:7/15/2008)... Fund Completion of Phase III Trials of Light Infu...tatic Colorectal Cancer and Phase I/II a... BELLEVUE, Wash., July 15 /- Light S...pany developing Light Infusion Therapy(TM),(Litx(T...nounced that it,has raised $40.1 million in a Seri...
(Date:7/15/2008)...Reports 92 Percent Response Rate to Combination Tr...ll/ -- Cephalon, Inc. (Nasdaq:,CEPH) announced tod...in the,Journal of Clinical Oncology, 92 percent of... cell non-Hodgkin,s lymphoma (NHL) responded to tr...e) for Injection plus rituximab.,This combination ...
(Date:7/14/2008)... VIEW, Calif., July 14 /- M...nounced it has initiated its,Phase 3 clinical prog...or,migraine., MAP0004 is orally inhaled and self-...oprietary Tempo(R) inhaler. In the company,s prior...ief in as fast as 10 minutes,with relief sustaine...
Breaking Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Light Sciences Oncology Raises $40.1 Million in Series C Financing 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 3Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 4Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 5MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 1Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 2Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 1AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 1American Chemical Societys Weekly PressPac Feb 6 2008 11486 2American Chemical Societys Weekly PressPac Feb 6 2008 11486 3American Chemical Societys Weekly PressPac Feb 6 2008 11486 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 5American Chemical Societys Weekly PressPac Feb 6 2008 11486 6American Chemical Societys Weekly PressPac Feb 6 2008 11486 7American Chemical Societys Weekly PressPac Feb 6 2008 11486 8American Chemical Societys Weekly PressPac Feb 6 2008 11486 9FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 1FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 2
...ne 4, 2007 – Data presented,today at this ye...ASCO) meeting in Chicago show that a novel combina...uorouracil (5-FU) therapy UFT,(tegafur–uraci...ponse rate in the first-line treatment of metastat...(Study of CPT-11 with Oxaliplatin combined,with UF...
...ne 4, 2007 – Genta,Incorporated (Nasdaq: GNT...ase 2 clinical trial of its marketed product, Gani...b (Rituxan®;,Genentech/IDEC) and dexamethasone...in’s lymphoma (NHL). The data were,presented...Clinical,Oncology (ASCO) in Chicago, IL. , ,Previo...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5
...oprotein hormone secreted by the anterior pituitar...cule is a noncovalently-linked dimer consisting of...etion are stimulated by gonadotropin-releasing hor... normally pulsatile, resulting in episodic release...
...vide high resolution typing of the entire locus wi...e tray reduces QC and testing costs while saving t...on results, no need for initial low resolution typ...que reaction pattern for most common alleles , Can...
...ide high resolution typing of the entire locus wit... tray reduces QC and testing costs while saving ti...n results, no need for initial low resolution typi...ue reaction pattern for most common alleles , Can ...
...full accordance with the relevant British Standard...performance means that by use of a Labcold British...ormally associated with plasma storage. At this te... time. Space saving, front opening format . Digita...
Medicine Products: